Chan et al. found that, in patients with nonalcoholic fatty liver disease, ezetimibe could not only reduce the intrahepatic triglyceride and plasma levels of hsCRP, IL-6 and RBP-4 but also increase the adiponectin, which attributed to the improvement of hepatic steatosis, hepatic inflammation, and dyslipidemia and increase in the insulin sensitivity [7]. The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatotic liver disease.